Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01034631 · ClinicalTrials.gov registry record · Phase 1
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
A Phase 1 study of Renal Cell Carcinoma, sponsored by Hoosier Cancer Research Network.
- Completed
- Registry status
- Phase 1
- Development phase
- 154
- Enrollment target
- 20
- Study locations
NCT01034631: Completed Phase 1 study of Renal Cell Carcinoma, sponsored by Hoosier Cancer Research Network.
NCT01034631 is a Phase 1 study of Renal Cell Carcinoma that has completed, run by Hoosier Cancer Research Network. The registered enrollment target is 154 participants, below the 242-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (36% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01034631, a Phase 1 study of Renal Cell Carcinoma, has completed, sponsored by Hoosier Cancer Research Network.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 154 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether BNC105P in combination with/following everolimus is effective in the treatment of progressive metastatic clear cell renal cell carcinoma following prior tyrosine kinase inhibitors.
Primary Outcome
Phase I
Conditions Studied
Interventions
- DRUG Everolimus
- DRUG BNC105P
Study Locations (20)
California
- Providence Health System: Roy and Patricia Disney Family Cancer Center - Burbank
- Compassionate Cancer Care Medical Group, Inc. - Corona
- Compassionate Cancer Care Medical Group - Corona
- City of Hope - Duarte
- Robert A. Moss, M.D., FACP, Inc. - Fountain Valley
- California Cancer Associates for Research and Excellence - Fresno
- Marin Specialty Care - Greenbrae
- Good Samaritan Hospital - Los Angeles
- UCLA Med - Hematology & Oncology - Los Angeles
- Compassionate Cancer Care Medical Group - Riverside
- American Institute of Research - Whittier
Florida
- Cancer Care Centers of Florida: Brooksville - Brooksville
- Broward Oncology Associates - Fort Lauderdale
- University of Florida, Shands Cancer Center - Gainesville
- Cancer Specialists of North Florida - Jacksonville
- Advanced Pharma CR, LLC - Miami
Colorado
- Centura Health Research Center - Denver
- Western Oncology & Hematology - Golden
Alabama
- Northwest Alabama Cancer Center - Muscle Shoals
Arkansas
- Genesis Cancer Center - Hot Springs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 154 participants |
| Start Date | 2010-01 |
| Est. Completion | 2016-12 |
| Phase | Phase 1 |
What the finished NCT01034631 record still lists
NCT01034631 is an interventional study that assigns participants to a tested intervention. The registered 154 participants enrollment target is mid-sized for trials with a published cap, below the 242-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (36% lower).
The record links to 1 condition, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Everolimus is the first listed.
NCT01034631 names 20 study sites across 5 states, led by California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT01034631 about?
NCT01034631 is a clinical study titled "BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma". The purpose of this study is to determine whether BNC105P in combination with/following everolimus is effective in the treatment of progressive metastatic clear cell renal cell carcinoma following prior tyrosine kinase inhibitors.
What is the current status of trial NCT01034631?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 154 participants. The study started on 2010-01. Estimated completion is 2016-12.
What conditions does trial NCT01034631 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma.
What interventions are being tested in trial NCT01034631?
The interventions under investigation include: Everolimus (DRUG), BNC105P (DRUG).
Who is sponsoring clinical trial NCT01034631?
This trial is sponsored by Hoosier Cancer Research Network, which has 26 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01034631 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01034631's enrollment target sits among peer trials
154 36th of 121 higher than 86 of 121 other Renal Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Renal Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
RECRUITING · Phase 1
-
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
RECRUITING · Phase 1
-
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
RECRUITING · Phase 1
-
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04300998 · 154 participants
Study of CAR-T Therapy in Older Patients
- NCT04597372 · 154 participants · Phase 2
Impact of Tamsulosin on Post-Operative Urinary Retention Following Pelvic Reconstructive Surgery
- NCT05294042 · 154 participants · NA
Patient Navigators for Children's Community Mental Health Services in High Poverty Urban Communities
- NCT05512390 · 154 participants · Phase 1
A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia